Delivery Order SPE2DB22D3016-SPE2DB25FBAQ8
- Not listed
- The Defense Logistics Agency awarded a $10,744.80 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $17,908.00 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vial 5ML, a rabies immunoglobulin product used in post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 19, 2025, and represents a continuation of the company's ongoing pharmaceutical supply relationship with federal healthcare systems. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,790.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside competitive award is scheduled for completion by October 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency has awarded a delivery order valued at $3,581.62 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. The non-competitive delivery order is scheduled for completion by June 23, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This award utilizes firm fixed pricing under a delivery order contract type, reflecting the standardized...
- The Defense Logistics Agency awarded a delivery order valued at $5,372.40 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,954.00 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immune globulin product used in post-exposure prophylaxis. This firm fixed price, non-competitive delivery order was executed on June 18, 2025, with an ultimate completion date of July 11, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate...
- The Defense Department's Medical Supply Chain awarded a delivery order valued at $7,163.24 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML, a rabies immune globulin product used in post-exposure prophylaxis treatment. Issued on September 7, 2025, with completion due by September 8, 2025, this firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency issued a delivery order valued at $3,465.10 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This non-set-aside, firm fixed-price delivery order was awarded on July 23, 2025, with an ultimate completion date of August 13, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. HYPERRAB is a rabies immunoglobulin (human) product used for post-exposure prophylaxis and...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for HYPERRAB 300 Unit/mL, a rabies immunoglobulin product, with a ceiling value of $18,711.54. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $10,744.80 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immune globulin product. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation and represents a direct procurement of critical immunological...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBAQ8Delivery Order
The Defense Logistics Agency awarded a $16,541.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 3mL, a rabies immunoglobulin product used in post-exposure prophylaxis. This non-set-aside competitive award is scheduled for completion by July 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting military and federal healthcare systems' medical supply requirements. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a critical pharmaceutical distributor, AmerisourceBergen leverages this comprehensive global pharmaceutical support vehicle to supply a broad range of medications, vaccines, and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's established relationship with DLA and demonstrated capability to fulfill federal procurement requirements through competitive processes position it as a key vendor for the military healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.5k | 6/30/25 |